Disufenton sodium (Cerovive)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 200721

CAS#: 168021-79-2 (sodium)

Description: Disufenton sodium, also known as Cerovive, OKN007, NXY-059, is a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin.

Chemical Structure

Disufenton sodium (Cerovive)
CAS# 168021-79-2 (sodium)

Theoretical Analysis

MedKoo Cat#: 200721
Name: Disufenton sodium (Cerovive)
CAS#: 168021-79-2 (sodium)
Chemical Formula: C11H13NNa2O7S2
Exact Mass:
Molecular Weight: 381.33
Elemental Analysis: C, 34.65; H, 3.44; N, 3.67; Na, 12.06; O, 29.37; S, 16.82

Price and Availability

Size Price Availability Quantity
25.0mg USD 150.0 Same day
50.0mg USD 250.0 Same day
100.0mg USD 350.0 Same day
200.0mg USD 550.0 Same day
500.0mg USD 950.0 Same day
1.0g USD 1650.0 Same day
2.0g USD 2650.0 2 Weeks
5.0g USD 5450.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 168021-79-2 (sodium)   168021-77-0 (free acid)    

Synonym: NXY059; NXY 059; NXY-059; CXY 059; CXY059; CXY-059; OKN007; OKN-007; OKN 007; ARL 16556; ARL16556; ARL-16556; CPI-22; CPI22; CPI 22; Cerovive; Disufenton sodium

IUPAC/Chemical Name: sodium (Z)-4-((tert-butyloxidoazanylidene)methyl)benzene-1,3-disulfonate


InChi Code: InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;;

SMILES Code: O=S(C1=CC=C(/C=[N+](C(C)(C)C)\[O-])C(S(=O)([O-])=O)=C1)([O-])=O.[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, DMF, PBS, and EtOH

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 381.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Lapchak PA, McKim JM Jr. CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut. Transl Stroke Res. 2011 Mar;2(1):51-59. PubMed PMID: 21494575; PubMed Central PMCID: PMC3074116.

2: Culot M, Mysiorek C, Renftel M, Roussel BD, Hommet Y, Vivien D, Cecchelli R, Fenart L, Berezowski V, Dehouck MP, Lundquist S. Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study. Brain Res. 2009 Oct 19;1294:144-52. doi: 10.1016/j.brainres.2009.07.035. Epub 2009 Jul 23. PubMed PMID: 19631615.

3: Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR; NXY-059 Efficacy Meta-analysis in Individual Animals with Stroke Investigators. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol. 2009 Aug;157(7):1157-71. doi: 10.1111/j.1476-5381.2009.00196.x. Epub 2009 Apr 27. PubMed PMID: 19422398; PubMed Central PMCID: PMC2743834.

4: Cheng YF, Jiang J, Hu P, Reinholdsson I, Guo W, Asenblad N, Nilsson D. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers. Clin Ther. 2008 Dec;30(12):2342-53. doi: 10.1016/j.clinthera.2008.12.013. PubMed PMID: 19167593.

5: Clausen F, Marklund N, Lewén A, Hillered L. The nitrone free radical scavenger NXY-059 is neuroprotective when administered after traumatic brain injury in the rat. J Neurotrauma. 2008 Dec;25(12):1449-57. doi: 10.1089/neu.2008.0585. PubMed PMID: 19118455.

6: Savitz SI. Cosmic implications of NXY-059. Stroke. 2009 Mar;40(3 Suppl):S115-8. doi: 10.1161/STROKEAHA.108.535112. Epub 2008 Dec 8. PubMed PMID: 19064771.

7: Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008 Oct;39(10):2824-9. doi: 10.1161/STROKEAHA.108.515957. Epub 2008 Jul 17. PubMed PMID: 18635842.

8: Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, HÃ¥rdemark HG, Rodichok L; SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008 Jun;39(6):1751-8. doi: 10.1161/STROKEAHA.107.503334. Epub 2008 Mar 27. PubMed PMID: 18369171.

9: Savitz SI, Fisher M. NXY-059 for the treatment of stroke. N Engl J Med. 2007 Nov 22;357(21):2198; author reply 2198-9. PubMed PMID: 18032772.

10: Mutch NJ, Moore NR, Mattsson C, Jonasson H, Green AR, Booth NA. The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro. Br J Pharmacol. 2008 Jan;153(1):124-31. Epub 2007 Nov 5. PubMed PMID: 17982476; PubMed Central PMCID: PMC2199381.

Additional Information